Information Provided By: 
Fly News Breaks for February 1, 2016
INSY
Feb 1, 2016 | 08:14 EDT
After surveying 40 doctors, including nine who prescribed large amounts of Insys' Subsys, RBC Capital says that payor pushback on the drug is "limited," while 95% of all the doctors surveyed and 89% of the high prescribers "intend to write as many or more Subsys prescriptions this year" as last year. The firm thinks the stock's valuation is attractive following its 61% pullback since July. It trimmed its price target on the stock to $44 from $49 but keeps an Outperform rating. .
News For INSY From the Last 2 Days
There are no results for your query INSY
